Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn …

RopeginterferonAlfa-2bAzacitidine+1 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07646821